Evidence map›Paper›PMID 31228095›Full record

ReviewCurrent hematologic malignancy reports2019

Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.

Wei Jiang, Barbara Withers, Gaurav Sutrave, Leighton E Clancy, Michelle I Yong, Emily Blyth

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei JiangFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Barbara WithersFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Gaurav SutraveFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Leighton E ClancyWestmead Institute of Medical Research, University of Sydney, Sydney, Australia.
Michelle I YongNational Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.
Emily BlythFaculty of Medicine and Health, The University of Sydney, Camperdown, Australia. emily.blyth@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewInfectious diseases contribute significantly to morbidity and mortality in recipients of allogeneic haematopoietic stem cell transplantation (aHSCT), particularly in the era of highly immunosuppressive transplant regimens and alternate donor transplants. Delayed cellular immune recovery is a major mechanism for the increased risk in these patients. Adoptive cell therapy with ex vivo manipulated pathogen-specific T cells (PSTs) is increasingly taking its place as a treatment strategy using donor-derived or third party-banked cells. RECENT

findingsThe majority of clinical trial data in the form of early-phase studies has been in the prophylaxis or treatment of cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus (AdV). Advancements in methods to select and enrich PSTs offer the opportunity to target the less common viral pathogens as well as fungi with this technology. Early clinical studies of PSTs targeting polyomaviruses (BK virus and JC virus), human herpesvirus 6 (HHV6), varicella zoster virus (VZV) and Aspergillus spp. have shown promising results in small numbers of patients. Other potential targets include herpes simplex virus (HSV), respiratory viruses and other invasive fungal species. In this review, we describe the burden of disease of this wider spectrum of pathogens, the progress in the development of manufacturing capability, early clinical results and the opportunities and challenges for implementation in the clinic.

Indexed as

AdenoviridaeAnimalsAntigens, ViralCytomegalovirusEpitopes, T-LymphocyteHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHost-Pathogen InteractionsHumansImmune ReconstitutionImmunocompromised HostImmunotherapy, AdoptiveOpportunistic InfectionsT-LymphocytesTransplantation, HomologousTreatment OutcomeAntigens, ViralEpitopes, T-LymphocyteAdoptive immunotherapyFungus-specific T cellsHaemopoietic stem cell transplantationImmune reconstitutionPathogen-specific T cellsVirus-specific T cells

Identifiers

PMID31228095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.